Humacyte Forecast, price target & analysts
Humacyte Target price 2026 - Analyst rating & recommendation
Humacyte Classifications & Recommendation
Humacyte Price Target
| Target Price | $1.28 |
| Price | $0.50 |
| Potential |
153.53%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Humacyte 2027 .
The average Humacyte target price is $1.28.
This is
153.53%
register free of charge
$4.20
735.16%
register free of charge
$1.01
100.84%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Humacyte to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Humacyte stock has an average upside potential 2027 of
153.53%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.04 | 3.57 |
| 75.15% | ||
| EBITDA Margin | -4,940.69% | -1,827.04% |
| 63.02% | ||
| Net Margin | -2,001.47% | -3,140.47% |
| 56.91% |
7 Analysts have issued a sales forecast Humacyte 2026 . The average Humacyte sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Humacyte EBITDA forecast 2026. The average Humacyte EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Humacyte Analysts have issued a net profit forecast 2026. The average Humacyte net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.26 | -0.40 |
| 79.37% | 53.85% | |
| P/E | negative | |
| EV/Sales | 36.41 |
7 Analysts have issued a Humacyte forecast for earnings per share. The average Humacyte EPS is
This results in the following potential growth metrics and future valuations:
Current Humacyte Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Benchmark |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jul 28 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Jun 17 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jun 16 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 11 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jun 08 2026 |
| Benchmark |
Locked
➜
Locked
|
Locked | Jun 01 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Benchmark:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jul 28 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Jun 17 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jun 16 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 11 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jun 08 2026 |
|
Locked
Benchmark:
Locked
➜
Locked
|
Jun 01 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
